sintilimab - Robuta Search

https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.941454/full Frontiers | Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab... Oro-maxillo-facial metastasis from hepatocellular carcinoma (HCC) are very rare, and reports on treating maxillary metastasis from HCC are unavailable. Anti-... comprehensive therapy frontiers encouraging efficacy consisting https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1534179/full Frontiers | Sintilimab for the treatment of lung adenocarcinoma-induced immune-related... Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce m... for the lung adenocarcinoma frontiers sintilimab treatment https://www.biospace.com/innovent-and-lilly-announce-successful-expansion-of-sintilimab-in-china-national-reimbursement-drug-list-to-include-three-additional-first-line-indications Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug... Dec 3, 2021 - Innovent Biologics, Inc. and Eli Lilly and Company, announce that the innovative PD-1 inhibitor sintilimab has been successfully included in the updated... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.991431/full Frontiers | Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell... Introduction: Radiotherapy may augment systemic antitumor responses to immunotherapy. We did a retrospective study to infer whether radiotherapy improves out... https://www.biospace.com/first-patient-dosed-in-a-phase-iii-trial-of-anti-pd-1-antibody-sintilimab-as-first-line-treatment-for-patients-with-advanced-squamous-non-small-cell-lung-cancer First Patient Dosed in a Phase III Trial of Anti-PD-1 Antibody Sintilimab as First-line Treatment... Oct 1, 2018 - Innovent Biologics, Inc. announced today that the first patient has been dosed in a phase III clinical trial (ORIENT-12) studying sintilimab, a fully human... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1527372/full Frontiers | Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent... BackgroundFibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted thera... systemic therapy https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1115109/full Frontiers | Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced... AbstractIntroduction Patients with intermediate or locally advanced hepatocellular carcinoma (HCC) who are not eligible for radical treatment typically have ... conversion therapy frontiers sintilimab plus lenvatinib https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.989966/full Frontiers | Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small... Immune checkpoint inhibitors (ICIs) have had a revolutionary effect on the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially...